| RFS | BCSS | |||
---|---|---|---|---|---|
Variable | No. | Hazard ratio (95Â % CI) | P | Hazard ratio (95Â % CI) | P |
pTNMa | 215 | Â | Â | Â | Â |
 0–1 |  | 1.0 |  | 1.0 |  |
 2 |  | 1.77 (0.89–3.53) | NS | 1.36 (0.49–3.80) | NS |
 3–4 |  | 4.09 (1.69–9.90) | <0.05 | 3.37 (1.30–9.31) | <0.05 |
HG | 215 | Â | Â | Â | Â |
 1 |  | 1.0 |  | 1.0 |  |
 2 |  | 2.35 (0.47–11.72) | NS | 1.84 (0.32–10.52) | NS |
 3 |  | 26.98(5.82–125.12) | <0.001 | 19.21 (4.15–88.90) | <0.001 |
Hormone receptor | 215 | Â | Â | Â | Â |
 ER+ PR+ |  | 1.0 |  | 1.0 |  |
 ER+ or PR+ |  | 1.53 (0.70–3.33) | NS | 1.63 (0.74–3.57) | NS |
 ER− PR− |  | 3.31 (1.28–8.58) | <0.05 | 2.94 (1.17–7.41) | <0.05 |
pCR | 215 | Â | Â | Â | Â |
 Yes |  | 1.0 |  | 1.0 |  |
 No |  | 1.53 (1.09–5.65) | <0.05 | 3.37(1.93–28.26) | <0.05 |
Surgery | 215 | Â | Â | Â | Â |
 Breast-conserving surgery |  | 1.0 |  | 1.0 |  |
 Modified mastectomy |  | 0.80 (0.33–1.92) | NS | 0.77 (0.29–2.05) | NS |
NLR (before NAC) | 215 | Â | Â | Â | Â |
 NLR < 2.1 |  | 1.0 |  | 1.0 |  |
 NLR ≥ 2.1 |  | 1.57 (1.05–3.57) | <0.05 | 2.21 (1.01–4.39) | <0.05 |
CRP (before NAC) | 215 | 1.02 (0.99–1.05) | NS | 1.00 (0.97–1.04) | NS |